|
Recommendations
| ShowHide Related Items >><< - $22.06 /
+2.195 (+11.05%) - 08/08/22
- Signify Health rises 14.5%
- 08/08/22
- Signify Health rises 15.9%
- 08/07/22
- Fly Intel: Top five weekend stock stories
- 08/03/22
- Signify Health sees FY HCS revenue $800M-$810M
- 08/07/22
- Fly Intel: Top five weekend stock stories
- 08/04/22
- CDW appoints Carolyn Wiesenhahn as CPO
- 08/03/22
- CVS Health says liquidity, cash position 'remain excellent'
- 08/03/22
- CVS Health says posted strong results across all business segments in Q2
- $22.06 /
+2.195 (+11.05%) - 08/08/22 Cowen
- Signify Health price target raised to $24 from $14 at Cowen
- 08/08/22 BofA
- CVS deal for Signify would help with continued evolution, says BofA
- 08/04/22 Piper Sandler
- Signify Health price target raised to $34 from $32 at Piper Sandler
- 07/28/22 RBC Capital
- Signify Health initiated with a Sector Perform at RBC Capital
- 08/08/22 BofA
- CVS deal for Signify would help with continued evolution, says BofA
- 08/04/22 Evercore ISI
- CVS Health removed from 'TAP Outperform' list at Evercore ISI
- 08/04/22 Deutsche Bank
- CVS Health price target raised to $120 from $113 at Deutsche Bank
- 07/21/22 Stifel
- Logical to see Oak Street, Cano as 'in play' after 1Life deal, says Stifel
- $22.06 /
+2.195 (+11.05%) - 08/03/22
- Signify Health reports Q2 EPS ($2.10), consensus 10c
- 05/04/22
- Signify Health reaffirms FY22 revenue view $948M-$971M, consensus $961.01M
- 05/04/22
- Signify Health reports Q1 EPS (6c), consensus 4c
- 03/02/22
- Signify Health sees FY22 revenue $948M-$971M, consensus $928.21M
- 08/03/22
- CVS Health raises FY22 revenue view to $307B-$312B from $305B-$310B
- 08/03/22
- CVS Health raises 2022 adjusted EPS view $8.40-$8.60 from $8.20-$8.40
- 08/03/22
- CVS Health reports Q2 adjusted EPS $2.40, consensus $2.17
- 08/02/22
- Notable companies reporting before tomorrow's open
- $22.06 /
+2.195 (+11.05%) - 08/07/22
- CVS planning to bid for Signify Health, WSJ reports
- 08/02/22
- Signify Health working with bankers on potential sale, WSJ reports
- 08/02/22
- Signify Health exploring options, including possible sale, WSJ says
- 08/07/22
- CVS planning to bid for Signify Health, WSJ reports
- 07/05/22
- 1Life Healthcare weighs options after drawing takeover interest, Bloomberg says
- 07/05/22
- 1Life Healthcare weighs options after drawing takeover interest, Bloomberg says
- 06/27/22
- CVS, Walmart rationing Plan B pills amid demand surge, WSJ reports
- $22.06 /
+2.195 (+11.05%) - 08/08/22
- What You Missed On Wall Street On Monday
- 08/08/22
- What You Missed On Wall Street This Morning
- 08/08/22
- Fly Intel: Pre-market Movers
- 08/03/22
- Fly Intel: After-Hours Movers
- 08/08/22
- What You Missed On Wall Street On Monday
- 08/08/22
- What You Missed On Wall Street This Morning
- 08/03/22
- What You Missed On Wall Street On Wednesday
- 08/03/22
- What You Missed On Wall Street This Morning
- 08/03/22
- Unusually active option classes on open August 3rd
- 07/14/22
- CVS Health call volume above normal and directionally bullish
- 06/02/22
- CVS Health put volume heavy and directionally bearish
- 05/04/22
- Unusually active option classes on open May 4th
|
|
Hot Stocks
| ShowHide Related Items >><< - 06/21/22
- Pacific Woodtech to acquire LP Building's EWP business for $210M
- 05/03/22
- Louisiana-Pacific sees Q2 adjusted EBITDA over $540M
- 03/04/22
- Resolutet acquires Louisiana-Pacific's 50% stake in Resolute-Engineered Wood JV
- 02/22/22
- Louisiana-Pacific sees FY22 CapEx $400M-$430M
- 06/29/22 Truist
- Louisiana-Pacific initiated with a Hold at Truist
- 06/23/22 TD Securities
- Louisiana-Pacific price target lowered to $75 from $85 at TD Securities
- 06/23/22 BofA
- Louisiana-Pacific downgraded to Neutral at BofA on housing slowdown
- 06/23/22 BofA
- Louisiana-Pacific downgraded to Neutral from Buy at BofA
- 06:15 Today
- Louisiana-Pacific reports Q2 adjusted EPS $4.19, consensus $4.40
- 05/03/22
- Louisiana-Pacific reports Q1 adjusted EPS $5.08, consensus $4.62
- 02/22/22
- Louisiana-Pacific sees Q1 adjusted EBITDA greater than $500M
- 02/22/22
- Louisiana-Pacific reports Q4 adjusted EPS $2.24, consensus $2.02
|
|
Earnings
| ShowHide Related Items >><< - 06/21/22
- Pacific Woodtech to acquire LP Building's EWP business for $210M
- 05/03/22
- Louisiana-Pacific sees Q2 adjusted EBITDA over $540M
- 03/04/22
- Resolutet acquires Louisiana-Pacific's 50% stake in Resolute-Engineered Wood JV
- 02/22/22
- Louisiana-Pacific sees FY22 CapEx $400M-$430M
- 06/29/22 Truist
- Louisiana-Pacific initiated with a Hold at Truist
- 06/23/22 TD Securities
- Louisiana-Pacific price target lowered to $75 from $85 at TD Securities
- 06/23/22 BofA
- Louisiana-Pacific downgraded to Neutral at BofA on housing slowdown
- 06/23/22 BofA
- Louisiana-Pacific downgraded to Neutral from Buy at BofA
- 05/03/22
- Louisiana-Pacific reports Q1 adjusted EPS $5.08, consensus $4.62
- 02/22/22
- Louisiana-Pacific sees Q1 adjusted EBITDA greater than $500M
- 02/22/22
- Louisiana-Pacific reports Q4 adjusted EPS $2.24, consensus $2.02
|
|
Hot Stocks
|
Google services appear to… ShowHide Related Items >><< - 08/08/22
- Clover Health CEO Vivek Garipalli to switch roles, Andrew Toy to succeed
- 08/02/22
- Mandiant to not provide guidance due to pending transaction with Google
- 08/02/22
- Thryv and Google team to streamline communication for small businesses
- 07/31/22
- Fly Intel: Top five weekend stock stories
- 08/08/22
- Clover Health CEO Vivek Garipalli to switch roles, Andrew Toy to succeed
- 08/02/22
- Mandiant to not provide guidance due to pending transaction with Google
- 07/31/22
- Fly Intel: Top five weekend stock stories
- 07/29/22
- Google says Stadia game streaming service not shutting down
- 08/03/22 Tigress Financial
- Alphabet price target raised to $186 from $183 at Tigress Financial
- 07/27/22 Truist
- Chrome cookie phase-out delay positive for Criteo, says Truist
- 07/27/22 KeyBanc
- Google's cookie phase-out delay not surprising, says KeyBanc
- 07/27/22 RBC Capital
- Google cookie phase-out delay adds another year of uncertainty, says RBC Capital
- 08/03/22 Tigress Financial
- Alphabet price target raised to $186 from $183 at Tigress Financial
- 07/27/22 Truist
- Chrome cookie phase-out delay positive for Criteo, says Truist
- 07/27/22 KeyBanc
- Google's cookie phase-out delay not surprising, says KeyBanc
- 07/27/22 RBC Capital
- Google cookie phase-out delay adds another year of uncertainty, says RBC Capital
- 07/26/22
- Alphabet reports Q2 EPS $1.21, consensus $1.30
- 07/26/22
- Notable companies reporting after market close
- 04/26/22
- Alphabet reports Q1 EPS $24.62, consensus $25.96
- 04/26/22
- Notable companies reporting after market close
- 07/26/22
- Alphabet reports Q2 EPS $1.21, consensus $1.30
- 07/26/22
- Notable companies reporting after market close
- 04/26/22
- Alphabet reports Q1 EPS $24.62, consensus $25.96
- 04/26/22
- Notable companies reporting after market close
- 08/08/22
- Google files two more patent lawsuits against Sonos, Bloomberg Law reports
- 08/04/22
- EU antitrust enforcers to investigate Google Play Store rules, Politico reports
- 08/02/22
- Rumble allowed to proceed with antitrust suit against Google, Verge reports
- 08/01/22
- Amazon hires senior congressional aide to fight antitrust bill, Bloomberg says
- 08/08/22
- Google files two more patent lawsuits against Sonos, Bloomberg Law reports
- 08/04/22
- EU antitrust enforcers to investigate Google Play Store rules, Politico reports
- 08/02/22
- Rumble allowed to proceed with antitrust suit against Google, Verge reports
- 08/01/22
- Amazon hires senior congressional aide to fight antitrust bill, Bloomberg says
- 08/08/22
- What You Missed On Wall Street On Monday
- 08/08/22
- What You Missed On Wall Street This Morning
- 08/04/22
- What You Missed On Wall Street This Morning
- 08/03/22
- #SocialStocks: Five-day trial between Twitter and Elon Musk set for October 17
- 08/08/22
- What You Missed On Wall Street On Monday
- 08/08/22
- What You Missed On Wall Street This Morning
- 08/04/22
- What You Missed On Wall Street This Morning
- 08/03/22
- #SocialStocks: Five-day trial between Twitter and Elon Musk set for October 17
- 07/26/22
- Alphabet options imply 6.1% move in share price post-earnings
- 07/25/22
- Unusually active option classes on open July 25th
- 07/25/22
- Alphabet put buyer realizes 47% same-day gains
- 07/22/22
- Unusually active option classes on open July 22nd
- 07/27/22
- Notable open interest changes for July 27th
- 07/26/22
- Alphabet Class A options imply 6.1% move in share price post-earnings
- 07/25/22
- Unusually active option classes on open July 25th
- 07/22/22
- Unusually active option classes on open July 22nd
|
|
Earnings
| ShowHide Related Items >><< - 06/09/22
- Patria Investments to acquire VBI Real Estate, terms not disclosed
- 05/10/22
- Patria Investments reports Q1 EPS 24c, consensus 18c
- 02/15/22
- Patria Investments reports Q4 EPS 19c, consensus 19c
|
|
Recommendations
| ShowHide Related Items >><< KEYS Keysight Technologies - 08/03/22
- Keysight, Nokia collaborate on public 800GE test
- 07/29/22
- The Digital IF Interoperability Consortium announces seven new members
- 07/13/22
- AI-LINK selects Keysight's 5G test tools for performance validation
- 06/22/22
- Keysight selected by Azcom for verifying O-RAN equipment
KEYS Keysight Technologies - 07/14/22 JPMorgan
- Keysight Technologies price target lowered to $176 from $200 at JPMorgan
- 06/17/22 UBS
- Keysight Technologies price target lowered to $177 from $220 at UBS
- 06/01/22 Goldman Sachs
- Keysight Technologies price target lowered to $165 from $185 at Goldman Sachs
- 05/18/22 JPMorgan
- Keysight Technologies price target lowered to $200 from $230 at JPMorgan
KEYS Keysight Technologies - 05/17/22
- Keysight Technologies sees FY22 EPS up 14%-15%, consensus $7.01
- 05/17/22
- Keysight Technologies sees Q3 EPS $1.74-$1.80, consensus $1.75
- 05/17/22
- Keysight Technologies reports Q2 EPS $1.83, consensus $1.67
- 02/17/22
- Keysight Technologies sees Q2 adjusted EPS $1.63-$1.69, consensus $1.64
KEYS Keysight Technologies - 03/11/22
- Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations
|
|
Earnings
|
Cuts FY22 revenue view to… ShowHide Related Items >><< - 08/08/22
- Clarivate selected by NLB to provide library solutions
- 07/21/22
- Clarivate awarded expanded license for domain service in China
- 07/11/22
- Clarivate CEO Jerre Stead retires, Jonathan Gear to succeed
- 05/09/22
- Wolters Kluwer partners with Clarivate to distribute Darts-ip in the U.S.
- 07/12/22 Wells Fargo
- Clarivate initiated with an Overweight at Wells Fargo
- 07/01/22 RBC Capital
- Clarivate price target lowered to $18 from $23 at RBC Capital
- 03/08/22 Stifel
- Clarivate price target lowered to $19 from $24 at Stifel
- 02/03/22 Citi
- Clarivate downgraded to Neutral at Citi with 'credibility clouded'
- 06:10 Today
- Clarivate reports Q2 adjusted EPS 22c, consensus 20c
- 05/09/22
- Clarivate reaffirms 2022 adjusted EPS view 85c-95c, consensus 87c
- 05/09/22
- Clarivate reports Q1 adjusted EPS 21, consensus 18c
- 03/10/22
- Clarivate backs FY22 adjusted EPS view 85c-95c, consensus 86c
|
|
Hot Stocks
|
July Local Billings were… ShowHide Related Items >><< - 06:10 Today
- Groupon sees 15%-20% sustainable annual adjusted EBITDA margins in 2023
- 08/08/22
- Groupon falls 6.9% to $12.92 after Q2 results and withdrawal of FY22 guidance
- 08/08/22
- Groupon reports Q2 billings down 26.7% y/y at $317.3M
- 08/08/22
- Groupon to cut $60M in tech costs, reduce North American sales force
- 05/10/22 Wedbush
- Groupon price target lowered to $15 from $22 at Wedbush
- 05/10/22 Barclays
- Groupon price target lowered to $12 from $20 at Barclays
- 05/10/22 Credit Suisse
- Groupon price target lowered to $23 from $29 at Credit Suisse
- 03/24/22 Ascendiant
- Groupon price target lowered to $30 from $35 at Ascendiant
- 08/08/22
- Groupon withdraws FY22 guidance, affirms FY23 targets.
- 08/08/22
- Groupon reports Q2 EPS (34c), consensus (44c)
- 05/09/22
- Groupon sees FY22 revenue $670M-$700M, consensus $837.08M
- 05/09/22
- Groupon reports Q1 EPS (80c), consensus (52c)
- 08/08/22
- Groupon lays off over 500 employees, TechCrunch reports
- 05/09/22
- Fly Intel: After-Hours Movers
- 04/11/22
- Fly Insider: Icosavax, Analog Devices among week's notable insider trades
- 02/28/22
- Fly Intel: After-Hours Movers
- 08/08/22
- Groupon options imply 14.1% move in share price post-earnings
- 08/08/22
- Unusually active option classes on open August 8th
- 05/09/22
- Groupon options imply 15.1% move in share price post-earnings
- 02/28/22
- Groupon options imply 12.0% move in share price post-earnings
|
|
Downgrade
| ShowHide Related Items >><< - 06/23/22
- Argo Group names Thomas Bradley CEO
- 04/28/22
- Argo Group initiates exploration of strategic alternatives
- 03/14/22
- Argo Group comments on director nominations from capital returns management
- 07/08/22 Raymond James
- Argo Group price target lowered to $45 from $60 at Raymond James
- 02/23/22 Compass Point
- Argo Group upgraded to Buy from Neutral at Compass Point
- 02/09/22 Raymond James
- Argo Group downgraded to Outperform from Strong Buy at Raymond James
- 02/08/22 Compass Point
- Argo Group downgraded to Neutral from Buy at Compass Point
- 08/08/22
- Argo Group reports Q2 operating EPS 89c vs $1.60 last year
- 05/02/22
- Argo Group reports Q1 operating EPS $1.24, consensus $1.10
- 02/22/22
- Argo Group reports Q4 operating EPS ($1.77), consensus ($2.66)
- 04/04/22
- Argo Group linked to Goldman as insurer explores options, The Insurer says
- 04/04/22
- What You Missed On Wall Street On Monday
- 04/04/22
- What You Missed On Wall Street This Morning
- 02/09/22
- Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations
|
|
Upgrade
| ShowHide Related Items >><< - 08/07/22
- Myovant Sciences, Pfizer receive FDA approval of MYFEMBREE
- 06/17/22
- Pfizer, Myovant Sciences announce results of Phase 3 SPIRIT 1, SPIRIT 2 studies
- 06/07/22
- Better Therapeutics appoints Karbe as Chief Executive Officer
- 06/02/22
- Pfizer, Myovant Sciences announce FDA approval of sNDA for MYFEMBREE
- 04/13/22 Baird
- Myovant Sciences price target lowered to $20 from $30 at Baird
- 09/09/21 SVB Leerink
- SVB Leerink starts Myovant at Market Perform
- 09/09/21 SVB Leerink
- Myovant Sciences initiated with a Market Perform at SVB Leerink
- 08/19/21 Goldman Sachs
- Myovant Sciences assumed with a Neutral at Goldman Sachs
- 05/10/22
- Myovant Sciences reports Q4 EPS (63c), consensus (57c)
- 04/12/22
- What You Missed On Wall Street On Tuesday
- 04/12/22
- What You Missed On Wall Street This Morning
- 04/12/22
- Fly Intel: Pre-market Movers
|
